Oral Therapies in MS.

Slides:

Advertisements

Similar presentations

FREEDOMS II TRIAL.

Advertisements

Fingolimod Therapy for Multiple Sclerosis

Multiple Scleroris Lyle Wiemerslage, PhD.

Multiple sclerosis: Oral Therapies and Beyond

The Nurse’s Role in Inflammatory Bowel Disease

CONCLUSION-DISCUSSION

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

PrEP: A Case-by-Case Approach

Highlights From the 2015 European Multiple Sclerosis Meeting

Perspectives on Key MS Data From the Annual European MS Meeting

Program Goals Teriflunomide: Pooled Safety Data.

Goals of Therapy for Patients With UC

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Improving Management of Rosacea From Therapeutics to Routine Skin Care

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

Immune Reconstitution in MS:

Current Controversies in Multiple Sclerosis Management

Applying Real-World Evidence in MS: Reviewing the State of the Art

Ask the Onychomycosis Expert, Part 2

Unmet Needs in the Secondary Prevention in ACS

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

T-Cell Directed Therapy in MS

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Patient-Centric Approach to the Management of Spasticity

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Are We Closer to Personalized Medicine in MS?

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

What Is the Role of Injectables in the Modern Era of MS Treatment?

Should I Stay or Should I Go?

Navigating New Oral Treatment Algorithms in CLL

Reversal Strategies for VKA: Truths and Misconceptions

Program Goals Disclaimer Overview Assessing Disease Activity.

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

Perspectives on the Impact of Inflammation in OA

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Treating to Target in MS

Management of Systematic Lupus Erythematosus

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Updates in Seizure Management

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

CAD and HF Often Coexist

Opportunistic Infections in MS What Is the Risk?

Clinical Pearls on Hot Topics in MS

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

LDL Cholesterol.

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Program Goal. Program Goal Disclaimer Overview.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Educational Objectives

Pathogenesis of IBD, and the Role of Biologic Therapies

AMD Therapy: Where Are We Now and Where Are We Going?

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Mitigating Infection Risk With DMT in MS

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Challenges and Emerging Solutions in Anemia Management Explored

Understanding the Role of Disability in MS Management

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Selective Immunomodulation in MS

Areas of Special Interest in PsO

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Oral Therapies in MS

Program Goals

Patient Case

Switching to an Oral DMT

Therapeutic Switching

Safety Concerns With Oral DMTs

Fingolimod Mechanism of Action

Fingolimod Routine Monitoring

Fingolimod Safety

Fingolimod Efficacy

Switching to Fingolimod

Teriflunomide Mechanism of Action

Teriflunomide Efficacy

Teriflunomide and NEDA

SIENA Analysis: The Effect of Teriflunomide on Brain Volume Loss

Comparing Oral Therapies

Dimethyl Fumarate Mechanism of Action

Dimethyl Fumarate Adverse Events

Dimethyl Fumarate Adherence

Dimethyl Fumarate Efficacy

Safety and Tolerability

PML

Tolerability

Therapeutic Sequencing

Case Continuation

Oral Therapies in the United States and Europe

Abbreviations

Abbreviations (cont)